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Abstract—The efﬁcacy of Quantiferon-TB gold test (QFT-GIT) remains to be documented in pe-
diatric population. Tuberculin skin test (TST) is a conventional test available for the diagnosis of
latent tuberculosis infection (LTBI). We aimed to investigate the concordance between QFT-GIT
and TST in children with and without tuberculosis infection. Ninety-seven patients, aged 3 months–
14 years, admitted to pediatric outpatient clinics of Dr. Sadi Konuk Training Hospital Bakırköy,
Turkey between March 2008 and April 2009 were recruited. Demographic features, TST results,
history of exposure to active tuberculosis (TB), chest X-ray ﬁndings, clinical history, presence of
Bacillus Calmette Guerin (BCG) vaccination scar were recorded. Patients were categorized into four
groups namely, active TB, LTBI, no TB and healthy. It was found that BCG scar positivity did not
inﬂuence QFT-GIT results. There was a statistically signiﬁcant agreement between QFT-GIT and
TST results (κ=0.486; p<0.01). In patients ≥5 years of age, TST positivity and QFT positivity had
a signiﬁcant relationship (p<0.01). In all patient groups, sensitivity and speciﬁcity was 65.85 % and
82.14 %, respectively. In active TB group, TST and QFT-GIT results demonstrated signiﬁcant
agreement ratio of 40.8 % (κ=0.364; p<0.01). Sensitivity and speciﬁcity was 100 % and 30 %,
respectively. Utilization of QFT-GIT in the diagnosis of LTBI reduces false-positive results and
prevents unnecessary treatment with INH and its adverse effects.
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INTRODUCTION
Number of cases with tuberculosis infection increased
at the beginning of 21st century. It is reported that one third
of world’s population is infected with Mycobacterium
tuberculosis and 1.7 million deaths worldwide are due to
active tuberculosis. It is documented that over 1 million
new cases of tuberculosis is diagnosed in children younger
than 15 years of age annually and active disease accounts
for 400,000 deaths in this population [1]. In Turkey, annual
number of new TB cases reported to World Health
Organization (WHO) is approximately 20.000; and the
incidence of TB is 30/100,000 [1].
TB is diagnosed by combining patient’s history of
exposure to active disease, tuberculin skin test (TST)
results, clinical and radiological ﬁndings. Microbiologic
tests yield positive results in only 30–40 % of cases [2].
TST poses some technical problems such as the potential
for false-positive and false negative results and problems
in administration and interpretation [2].
Identiﬁcation of Early Secreted Antigenic Target-
6 kD protein (ESAT-6) and Culture Filtrate Protein-10
kD (CFT-10) has been a promising development in the
diagnosis of TB. These antigenic proteins are encoded
within the region of difference 1 (RD 1) of the M.
tuberculosis genome. Neither of these proteins exist in
Bacillus Calmette Guerin (BCG) and non-tuberculosis
mycobacteria making them more speciﬁc tools in the
diagnosis of M. tuberculosis [3]. Quantiferon-TB gold
test (QFT-GIT), licensed by FDA in 2004, utilizes ESAT-6,
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CFT-10 and TB7.7 antigens for stimulating in vitro release
of γ-IFN frommemory Tcells [4]. Released γ-IFN level is
measured by enzyme-linked immunosorbent assay
(ELISA) method. Majority of the research about γ-IFN
was conducted in countries of low TB incidence and
mainly in adults. However, in countries such as Turkey
where TB is endemic, more studies are required to
document the efﬁcacy of QFT-GIT in pediatric population.
We aimed to investigate the agreement between
QFT-GIT and TST results in children with and without
tuberculosis infection.
MATERIALS AND METHODS
Ninety-seven patients admitted to pediatric outpa-
tient clinics of Dr. Sadi Konuk Training Hospital in
Bakırköy, Turkey between March 2008 and April 2009
were enrolled. The age of the patients ranged from
3 months to 14 years. Demographic features, TST
results, history of exposure to active tuberculosis (TB),
chest X-ray ﬁndings, clinical history, presence of BCG
vaccination scar were recorded. Patients were catego-
rized into four main groups namely, active TB, latent
tuberculosis infection (LTBI), no TB, and healthy.
Group I (n=30): Active TB; patients with signs and
symptoms suggestive of TB and diagnostic
work-up yielded the diagnosis of TB, ﬁnally
anti-TB chemotherapy started.
Group II (n=15): LTBI, patients were asymptomatic but
TST results were positive.
Group III (n=27): Non-TB, patients with signs and
symptoms suggestive of TB however diag-
nostic work-up excluded the disease.
Group IV (n=25): Healthy children.
Written parental informed consent was obtained for
each patient. The study was approved by the hospital
ethics committee.
Exclusion Criteria Patients with hemodynamically unstable
cardiopulmonary disease, history of severe allergic reaction
to puriﬁed protein derivatives (PPD), history of active TB,
immunodeﬁciency, malnutrition and patients whose parent/
guardian refused to consent were excluded.
TST Administration Tuberculin skin test was performed
on the volar aspect of the forearm by administering
0.1 ml (5 tuberculin units) of PPD solution intradermal-
ly. Vertical and horizontal diameter of the induration was
measured 48–72 h after the injection by using the ball
point pen method.
TST result ≥10 mm was considered positive in
patients without a BCG vaccination scar and TST result
≥15 mm was considered positive in patients with BCG
vaccination scar. In patients with BCG vaccination scars,
TST <15 mm was considered negative [5].
QFT
The QFT assay was performed as per the manufac-
turer’s instructions. The assay involved two stages: the ﬁrst
stage involved incubation of whole blood with antigens,
and the second stage involved measurement of IFN-g
production in harvested plasma by ELISA. Venous blood
was directly collected, prior to TST administration, into
three 1-ml heparin-containing tubes. One tube contained
only heparin as negative control, another also contained
mitogen as positive control, and the third tube had
overlapping peptides representing the entire sequences of
ESAT-6 and CFP-10 and another peptide from a portion of
the TB antigen TB7.7 (Rv2654). Within 2–6 h of blood
draw, the tubes were incubated at 37°C. After exactly 24 h
of incubation, the tubes were centrifuged and plasma was
harvested and frozen at −70°C until the ELISA was
performed (on average, ELISA was performed within 4–
6 weeks of blood collection). The γ-INF response was
quantiﬁed using ELISA (Cellestis Ltd, Carnegie, Victoria,
Australia). γ-INF values (in international units per milli-
liter) for TB-speciﬁc antigens and mitogen were corrected
for back ground by subtracting the value obtained for the
respective negative control. As recommended by the
manufacturer, and based on previous studies, the cut-off
value for a positive test was γ-INF≥0.35 IU/ml [6, 7].
Statistical Analysis NCSS 2007 and PASS 2008 Statistical
Software (Utah, USA) program was used for statistical
analysis. Because there is no gold standard for diagnosis of
LTBI, concordance between TST and QFT-GIT was
assessed by using proportion agreement and kappa
coefﬁcients. Chi-square and Fisher’s exact tests were used
for categorical variables. A p value of less than 0.05 was
considered signiﬁcant and results were reported with 95 %
conﬁdence intervals.
RESULTS
A total of 97 patients were enrolled. Forty eight
(49.5 %) patients were female. Age and gender of
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the patients did not differ signiﬁcantly (p>0.05;
Table 1).
Number of positive QFT results differed signiﬁcantly
between groups (p<0.01) QFT positivity rate was signif-
icantly higher in group I and II compared to other groups.
Rate of indeterminate test results was signiﬁcantly higher
in group III compared to other groups (Fig. 1, Table 1).
TST positivity was different between groups (p<0.01).
The number of positive TST results was signiﬁcantly lower
in group IV compared to other groups (Fig. 2, Table 1).
Numbers of BCG vaccination scar-positive children were
close in study groups (p>0.05; Table 1). History of
exposure to active TB was signiﬁcantly different between
all groups (p<0.01), it was especially low in group IV
(Table 1). Chest X-ray abnormalities were observed in
83.3 %, 0 %, and 59.3 % of cases with active TB, LTBI,
and non-TB, respectively (p<0.01; Table 1).
In all cases and groups, presence of BCG
vaccination scar inﬂuenced neither TST nor QFT
results (p>0.05). QFT results were not affected by
TST induration diameters; rate of QFT positivity was
signiﬁcantly higher in patients with an induration
diameter of 10–14 and ≥15 mm compared to other
diameters (Table 2).
In active disease group; QFT results were positive
in all patients with positive TST results. In LTBI group,
TST positivity was not associated with QFT positivity
(p>0.05). In non-TB group, there was not a signiﬁcant
relationship between TST positivity and QFT positivity
(p>0.05). When all cases were considered; there was a
signiﬁcant relationship between TST positivity and
QFT positivity (p<0.01); TST positivity rate was
signiﬁcantly higher in patients with positive QFT
results (Table 3).
Table 1. Demographic and Clinical Features of Patients
Active TB LTBI Healthy Non-TB Total χ2; p
N 30 15 25 27 97
Gender, n (%)
Female 15 (50%) 8 (53.3%) 10 (40%) 15 (55.6%) 48 (49.5%) χ2=1.39; p=0.708
Male 15 (50%) 7 (46.7%) 15 (60%) 12 (44.4%) 49 (50.5%)
Age, n (%)
<5 9 (30%) 2 (13.3%) 4 (16%) 8 (29.6%) 23 (23.7%) χ2=2.89; p=0.408
≥5 21 (70%) 13 (86.7%) 21 (84%) 19 (70.4%) 74 (76.3%)
QFT, n (%)
Positive 27 (90%) 10 (66.7%) 0 (0%) 0 (0%) 37 (38.1%) χ2=73.08; p=0.001**
Negative 3 (10%) 5 (33.3%) 23 (92%) 23 (85.2%) 54 (55.7%)
Indeterminate – – 2 (8%) 4 (14.8%) (6.2%)
TST, n (%)
Positive 20 (66.7%) 12 (80%) 0 (0%) 9 (33.3%) 41 (42.3%) χ2=35.25; p=0.001**
Negative 10 (33.3%) 3 (20%) 25 (100%) 18 (66.7%) 56 (57.7%)
BCG vaccination scar, n (%)
Positive 24 (80%) 14 (93.3%) 23 (92%) 24 (88.9%) 85 (87.6%) χ2=2.54; p=0.468
Negative 6 (20%) 1 (6.7%) 2 (8%) 3 (11.1%) 12 (12.4%)
History of exposure, n (%)
Positive 18 (60%) 9 (60%) 0 (0%) 10 (37%) 37 (38.1%) χ2=24.54; p=0.001**
Negative 12 (40%) 6 (40%) 25 (100%) 17 (63%) 60 (61.9%)
Chest X-ray, n(%)
Positive 25 (83.3%) 0 (0%) – 16 (59.3%) 41 (56.9%) χ2=28.42; p=0.001**
Negative 5 (16.7%) 15 (100%) – 11 (40.7%) 31 (43.1%)
Χ2 Chi-square test
**p<0.01
Fig. 1. Distribution of QFT results for all groups of patients.
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In active disease group, non-incidental agreement rate
between TST and QFTwas 40.8 % (κ=0.364; p<0.01). In
this group, sensitivity (i.e., rate of positive QFT results in
patients with positive TST results) was 100 % and
speciﬁcity (i.e., rate of negative QFT results in patients
with negative TST results) was 30 %. Positive predictive
value was 74.07 %; negative predictive value was,
accuracy of the test was 76.7 % (Table 3).
In LTBI group, non-incidental agreement rate be-
tween TST and QFTwas −33.3 % (κ=−0.333 p>0.05). In
this group sensitivity was 58.33 % and speciﬁcity was 0 %.
Positive predictive value was 70 %; negative predictive
value was 0 %, the accuracy of the test was 46.67 %
(Table 3).
In all cases, non-incidental agreement rate between
TST and QFT was 48.6 % (κ=0.486; p<0.01). In this
group, sensitivity was 65.85 % and speciﬁcity was
82.14 %. Positive predictive value was 72.97 %;
negative predictive value was 76.67 %, the accuracy of
the test was 75.26 % (Table 3).
In patients <5 years of age, there was not a
signiﬁcant relationship between TST positivity and
QFT positivity (p>0.05). Non-incidental agreement rate
between TST and QFT was 25.1 % (κ=0.251; p>0.05).
In this group, sensitivity was 42.85 %; speciﬁcity was
92.5 %. Positive predictive value was 50 %; negative
predictive value was 90.24 %; the accuracy of the test
was 85.1 % (Table 4).
In patients ≥5 years of age; there was a signiﬁcant
relationship between TST positivity and QFT positivity
(p<0.01); positive TST result rates were signiﬁcantly
higher in patients with positive QFT results. Non-
incidental agreement rate between TST and QFT was
53.4 % (κ=0.534; p<0.01). In this group, sensitivity
was 70.58 %; speciﬁcity was 82.50 %. Positive
predictive value was 77.41 %; negative predictive value
was 74.74 % and the accuracy of the test was 77.03 %
(Table 4)
DISCUSSION
Recently emerged tests, based on measuring in vitro
release of IFN-γ from T- lymphocytes upon exposure to
mycobacterial antigens, are considered as promising
alternative tools to TST in the diagnosis of TB.
Several authors have emphasized that BCG
vaccination leads to false positive TST results and
they reported that speciﬁcity of IFN-γ release assays
(IGRA) might be higher [8–10]. TST induration
diameter is inﬂuenced by the age at which the ﬁrst
BCG dose is received, interval between two doses,
and amount of the administered vaccine dose [11,
12]. It is reported that in developed countries, BCG
vaccination at birth or during infancy does not affect
TST results [7]; however, BCG vaccination affects
the sensitivity of TST in underdeveloped and devel-
oping countries [1, 13].
It is clearly documented that BCG vaccination does
not affect QFT test results [14–18]. Our results parallels
the results of previous research and indicates that BCG
Fig. 2. Distribution of TST results for all groups of patients.
Table 2. Agreement Between TST and QFT Results
QFT
Diameter of induration (mm)
p
0–5 5–9 10–14 ≥15 Total
n (%) n (%) n (%) n (%) n (%)
Positive 4 (12.5%) 0 (0%) 7 (50%) 26 (65%) 37 (38.1%) 0.001**
Negative 26 (81.3%) 10 (90.9%) 6 (42.9%) 12 (30%) 54 (55.7%)
Indeterminate 2 (6.3%) 1 (9.1%) 1 (7.1%) 2 (5%) 6 (6.2%)
Total 32 (100%) 11 (100%) 14 (100%) 40 (100%) 97 (100%)
**p<0.01
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vaccination status and QFT results do not pose a
statistically signiﬁcant relationship (p>0.05). In popula-
tions of widespread BCG vaccine use, QFT may be an
alternative tool to TST in the diagnosis of TB.
It is clearly stated in the guideline of Centers for
Disease Control and Prevention that since the sensitiv-
ities are rather suboptimal, negative QFT and TST
results do not rule-out active TB [19]. In various studies
comparing TST and QFT, sensitivity was found to be
between 55–88 % and mean value of sensitivity was
75 % [20]. Indeterminate results observed in 7 % of
patients were attributed to the immunosuppresion due to
active TB. It is observed that indeterminant results are
detected more frequently in studies encompassing
patients with immunodeﬁciency [20]. In our study, none
of the results were indeterminate in patients with active
TB. This ﬁnding might be attributed to the fact that
patients with immunodeﬁciency were excluded from our
study.
In Japan, Kobashi et al. conducted a study which
included 50 healthy volunteers, 50 patients with active TB,
and 100 patients with non-TB infections and emphasized
that QFT is superior to TST in differentiating active TB
from non-TB Mycobacterium infections [21].
Higucki et al. compared TST and QFT results of
college students who had a history of exposure to an
index case with active TB and followed-up these
students for 3.5 years. In conclusion, authors recom-
mended utilization of QFT instead of TST while
investigating children with a history of exposure to
active TB and they proposed that positive TST results
should be conﬁrmed via QFT [22].
Mazurek et al. published a QFT-G instruction
guideline in 2005. In this guide, they reported that
QFT-G, similar to TST, was not an effective tool for
differentiating LTBI from active TB and stressed the
importance of utilizing radiologic examinations, clinical
ﬁndings, microbiologic, and cytologic investigations for
a ﬁrmly established diagnosis of TB. The authors
reported that neither negative TST results, nor negative
QFT results excluded diagnosis of TB infection and
added that in the presence of symptoms and signs
suggesting diagnosis of TB, negative TST or QFT results
might not rule-out TB infection. They also reported the
importance of HIV testing in suspicious cases [23]. In
our study, non-incidental agreement rate between TST
and QFT was −33.3 % (κ=−0.333 p>0.05) in LTBI
group; sensitivity was 58.33 % and speciﬁcity was 0 %.
Positive predictive value was 70 %; negative predictive
value was 0 %, the accuracy of the test was 46.67 %. TB
prevention programs recommend QFT for the follow-up
of LTBI in patients with a history of exposure to active
disease because QFT makes a second visit unnecessary,
is more speciﬁc than TST and—contrary to TST—does
not have a booster effect [23]. Our ﬁndings support this
recommendation.
Table 3. Agreement Between QFT and TST Results
Variable n Kappa value (p value) Positive agreement % Negative agreement % TST/−QFT % −TCTD/+QFT % Accuracy (%)
Active TB 29 κ=0.364; p=0.006** 100 30.00 74.07 100 76.67
LTBI 15 κ=−0.333; p=0.171 58.33 0 70.0 0 46.67
All cases 97 κ=0.486; p=0.001** 65.85 82.14 72.97 76.67 75.26
**p<0.01




n (%) n (%) n (%)
<5 years QFT Positive 3 (42.9%) 3 (42.9%) 6 (26.1%) 0.318
Negative 4 (57.1%) 13 (81.3%) 17 (73.9%)
Total 7 (100%) 16 (100%) 30 (100%)
≥5 years QFT Positive 24 (70.6%) 7 (17.5%) 31 (41.9%) 0.001**
Negative 10 (29.4%) 33 (82.5%) 43 (57.1%)
Total 34 (100%) 40 (100%) 74 (100%)
Fisher’s exact test and Chi-square tests were used
*p<0.05
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One of the 26 healthy children had a positive QFT
result. Although he did not have any signs and
symptoms of infection, chest X-ray, and thorax CT
ﬁndings revealed active TB and anti-tuberculous che-
motherapy was commenced promptly. This patient was
assigned as healthy when symptoms, history of expo-
sure, TST result and physical examination ﬁndings were
evaluated. The patient was diagnosed incidentally by
QFT. This ﬁnding indicates that QFT, as well as TST,
may be used in routine screening of TB in our country.
Two of the remaining 25 patients had indeterminate
results. Since these patients did not have any clinical
features suggestive of TB, repeat QFT was not
performed as recommended previously [23].
Connel et al. stated that rate of QFT positivity and
mitogen response increased with advancing age [7].
Nakaoka et al. reported a decreased response to QFT in
children <5 years of age [24]. Ulrich et al. declared that
publications indicating a lower response rate to QFT in
infants and young children were scarce and more research
was needed on that issue [25]. In 2009, Bianchi et al.
reported that sensitivity of IGRAwas higher compared to
TST in children less than 4 years of age [26]. In our study,
agreement between QFT and TST was 53.4 % (κ=
0.251; p>0.05) in patients older than 5 years of age and
it was 25.1 % (κ=0.534; p<0.01) in patients younger
than 5 years of age. The agreement in patients older
than 5 years of age was signiﬁcant compared to patients
younger than 5 years of age. Finally, it can be proposed
that QFT may be used routinely for TB monitoring in
Turkish children, especially those older than 5 years of
age.
It is shown that TST induration diameter and QFT
results correlate well [27, 28]. Johnson et al. failed to
document a signiﬁcant relationship between TST and
QFT results [29]. In our study, QFT positivity differed
signiﬁcantly according to TST induration diameter: QFT
positivity rate was signiﬁcantly higher in patients with
an induration diameter of 10–14 and ≥15 mm compared
to other diameters (p=0.001). Although QFT-G use is
not widespread in our country, children with a TST
result between 10 and 14 mm should be followed-up
closely.
In literature, a substantially signiﬁcant agreement
was documented between QFT and TST results [10, 30,
31]. We observed in our study that non-incidental
agreement between QFT and TST was 48.6 % and it
was statistically signiﬁcant (κ=0.486; p<0.01). In this
group, sensitivity was 65.85 % and speciﬁcity was
82.14 %. Positive predictive value was 72.97 %;
negative predictive value was 76.67 %, the accuracy of
the test was 75.26 %.
To conclude, IFN-γ release assays may have
numerous advantages over TST such as higher speciﬁc-
ity, better relationship with M. tuberculosis exposure,
and lower cross-reaction rates with BCG vaccination and
NTM. Tests based on measurement of released IFN-γ
may reduce false-positive results and prevent unneces-
sary treatment with INH and its adverse effects.
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